Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Deadly Drug-Resistant Strain of Escherichia coli Emerged as a Single Genetic Clone

By LabMedica International staff writers
Posted on 02 Jan 2014
Molecular microbiologists working with advanced genomic research tools have shown that an extremely virulent and drug-resistant strain of Escherichia coli appeared about 10 years ago following mutations in two genes.

Previous studies on the H30-Rx clone of the ST131 strain of E. More...
coli using pulsed-field gel electrophoresis (PFGE) had indicated that characteristics such as propensity for extraintestinal infections, fluoroquinolone resistance, and extended-spectrum beta-lactamase (ESBL) production had arisen as a series of independent genetic events. If this conclusion were correct, it would suggest that the existence of many different intermediate strains would exist with multiple pathways for evading the immune system and medical treatment.

However, in a new study published in the December 17, 2013, edition of the journal mBio, investigators at George Washington University School of Public Health (Washington DC, USA) and their colleagues at the University of Minnesota (Minneapolis, USA) used the advanced genomic technique, whole-genome sequencing, to reconstruct the evolutionary history of the ST131 clone. The investigators analyzed the genomes of samples of E. coli collected from patients and animals in five countries over the 44-year period, 1967–2011.

They found that fluoroquinolone resistance was confined almost entirely to a single, rapidly expanding ST131 subclone, designated H30-R. This clone, which was fully resistant to the drug ciprofloxacin, soon morphed into a new clone called H30-Rx, which was resistant to several extended-spectrum antibiotics, such as third-generation cephalosporins.

The investigators believe that the clonal nature of H30-Rx may provide opportunities for vaccine or transmission prevention-based control strategies, which could gain importance as H30-Rx and other extraintestinal pathogenic E. coli subclones become resistant to an increasing number of antibiotics.

"This strain of E. coli spreads from person to person and seems to be particularly virulent," said contributing author Dr. James R. Johnson, professor of medicine at the University of Minnesota. "This study might help us develop better tools to identify, stop or prevent its spread by finding better ways to block the transmission of the superbug, or by finding a diagnostic test that would help doctors identify such an infection early on, before it might have the chance to turn lethal."

Related Links:

George Washington University School of Public Health
University of Minnesota



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.